DK149890B - Analogifremgangsmaade til fremstilling af n-(4-phenyl-2-thiazolyl)-oxamidsyre-2-ethoxyethylester - Google Patents
Analogifremgangsmaade til fremstilling af n-(4-phenyl-2-thiazolyl)-oxamidsyre-2-ethoxyethylester Download PDFInfo
- Publication number
- DK149890B DK149890B DK320081A DK320081A DK149890B DK 149890 B DK149890 B DK 149890B DK 320081 A DK320081 A DK 320081A DK 320081 A DK320081 A DK 320081A DK 149890 B DK149890 B DK 149890B
- Authority
- DK
- Denmark
- Prior art keywords
- phenyl
- acid
- thiazolyl
- preparation
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 150000002148 esters Chemical class 0.000 title description 3
- PKWXTLHKQFEOJK-UHFFFAOYSA-N n'-(4-phenyl-1,3-thiazol-2-yl)oxamide Chemical compound S1C(NC(=O)C(=O)N)=NC(C=2C=CC=CC=2)=C1 PKWXTLHKQFEOJK-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 15
- -1 2-substituted thiazol-2-yl-oxamic acid esters Chemical class 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000172 allergic effect Effects 0.000 abstract description 2
- 208000010668 atopic eczema Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical class NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000003266 anti-allergic effect Effects 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
- 229940093475 2-ethoxyethanol Drugs 0.000 description 2
- ZOOQXNXFZXSKMS-UHFFFAOYSA-N 2-ethoxyethyl 2-oxo-2-[(4-phenyl-1,3-thiazol-2-yl)amino]acetate Chemical compound S1C(NC(=O)C(=O)OCCOCC)=NC(C=2C=CC=CC=2)=C1 ZOOQXNXFZXSKMS-UHFFFAOYSA-N 0.000 description 2
- PYSJLPAOBIGQPK-UHFFFAOYSA-N 4-phenyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1 PYSJLPAOBIGQPK-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DCANGVYZWYRVOB-UHFFFAOYSA-N 2-amino-2-oxoacetyl chloride Chemical compound NC(=O)C(Cl)=O DCANGVYZWYRVOB-UHFFFAOYSA-N 0.000 description 1
- FPAJNHLSMGQZOI-UHFFFAOYSA-N 2-ethoxyethyl 2-amino-2-oxoacetate Chemical compound C(C(=O)N)(=O)OCCOCC FPAJNHLSMGQZOI-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229950003476 aminothiazole Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- JSDDXJXVRWCEBV-UHFFFAOYSA-N ethyl 2-oxo-2-[(4-phenyl-1,3-thiazol-2-yl)amino]acetate Chemical compound S1C(NC(=O)C(=O)OCC)=NC(C=2C=CC=CC=2)=C1 JSDDXJXVRWCEBV-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Description
i 149890
Opfindelsen angår en analogifremgangsmåde til fremstilling af den hidtil ukendte N-(4-phenyl-2-thiazolyl)-ox-amidsyre-2-ethoxyethylester, der er et lægemiddel, der kan anvendes ved behandlingen af allergiske sygdomme.
5 Der kendes en hel række derivater af oxamidsyre og este re heraf, idet der f.eks. i tysk offentliggørelsesskrift nr. 24 13 966 er beskrevet aryl- og hetary1-derivater, thiazol-derivater i tysk offentliggørelsesskrift nr.
28 28 091 og i den offentliggjorte europæiske patent-10 anmeldelse nr. 0006368 og benzothiazol-derivater i de tyske offentliggørelsesskrifter nr. 27 31 441 og 26 36 486, idet forbindelserne finder anvendelse ved bekæmpelse eller undertrykkelse af allergiske reaktioner. Deres virkning er imidlertid ikke altid tilfreds- 13 stillende.
Det har nu vist sig, at N-(4-phenyl-2-thiazolyl)-oxamid- syre-2-ethoxyethylester (formel I)
Orv '—' € nh-co-coo-c2h4oc2h5 udviser særdeles værdifulde egenskaber, specielt som antiallergikum, og er 200 gange kraftigere virkende 20 end f.eks. forbindelsen fra ovennævnte europæiske patentanmeldelse.
Fremgangsmåden ifølge opfindelsen er ejendommelig ved det i kravets kendetegnende del angivne.
Ved fremgangsmåde a) omsætter man på i og for sig kendt 25 måde 2-amino-4-phenylthiazol med formlen II
149890 2 ^S/^NH2
med et oxalsyreesterhalogenid med formlen III
C-H^OC^-O-C-C-Hal III,
II II
o o hvori Hal betegner et halogenatom, fortrinsvis et chlor-atom, hensigtsmæssigt i et opløsningsmiddel og i nærværelse af en syreacceptor.
5 Velegnede opløsningsmidler er f.eks. methylenchlorid, chloroform, carbontetrachlorid, 1,2-dichlorethan, 1,1,1-trichlorethan, eddikesyreethylester, dimethylformamid, dimethylacetamid, N-methylpyrrolidon, tetrahydrothio-phendioxid, hexamethylphosphorsyretriamid, tetrahydro-10 furan, dioxan eller blandinger heraf. Eksempler på syreacceptorer er triethylamin, tributylamin og pyridin. Reaktionen mellem aminothiazolen II og oxalylhalogeni-derne III gennemføres fortrinsvis ved forholdsvis lave temperaturer, idet temperaturer mellem 0 °C og 30 °C 15 ' er velegnede. I stedet for de frie aminothiazoler kan man anvende hydrochlorider, dersom man anvender et yderligere ækvivalent base.
Den omhandlede oxamidsyreester I kan også fremstilles ved fremgangsmåde b) på i og for sig kendt måde ud fra 20 den tilsvarende frie oxamidsyre efter overførsel til oxamidsyrechloridet ved forestring med 2-ethoxyethanol i nærværelse af et syrebindende middel, som triethylamin.
Ved fremgangsmåde c) forestres den under b) nævnte oxamidsyre med 2-ethoxyethanol direkte i nærværelse af en 149830 3 sur katalysator eller et carbodiimid til opnåelse af forbindelsen med formlen I som beskrevet i Chem. Ber.
100 (16) 1967 eller i Acta Chem. Scand. B 22 410 (1979).
Den som udgangsforbindelse anvendte 2-amino-4-phenyl-5 thiazol (II) er en kendt forbindelse.
Den omhandlede forbindelse I udviser antiallergiske egenskaber, hvorfor den er et værdifuldt lægemiddel ved behandlingen af allergiske sygdomme i respirations- og mave-tarm-kanalen og på huden, f.eks. af allergisk 10' astma, allergisk rhinitis eller ved fødevare-allergier.
I forhold til det velkendte antiallergikum Cromolyne udviser den omhandlede forbindelse i dyreforsøg i det passive cutane rotteanaphylaxi-forsøg sig at være oralt virksom og yderligere at have en væsentlig længe-15 re virkningstid.
Den antiallergiske virkning afprøvedes på rotter. Til afprøvningen anvendtes modellen med det passive cutane anaphylaxi-forsøg (PCA).
Narkotiserede hanrotter (100 til 140 g) sensibilise-20 redes ved intradermal injektion (barberet ryghud) af 0,1 ml af et ovalbumin-antiserum. Efter sensibiliseringsperioden på ca. 48 timer skete behandlingen (intraperitoneal eller peroral indgift) med forskellige doser (10 dyr/dose) af farsøgsforbindelsen. 15 25 eller 20 minutter efter behandlingen injiceredes en antigen/evansblå blanding (10 mg/kg ovalbumin i 2 pro-centig evansblå-opløsning) intravenøst i forsøgsdyrene.
30 minutter senere aflivedes dyrene, ryghuden fjernedes, og på den indre overflade måltes diameteren af de 30 cirkelformede blåfarvninger. Farveplettens størrelse på de ubehandlede kontroldyr er standardiserbar. Den antiallergisk virkende forbindelse formindsker dosis- 149890 4 afhængigt farveplettens diameter. Som ED 50 % angives den dosis, der i sammenligning med de medikamentøst u-behandlede kontroldyr formindsker farveplettens diameter med 50 %.
5 Ud over de antiallergiske virkninger undersøgtes den akutte toxicitet på grupper på hver 2 NMRI-mus, vægt 20-26 g, ved intraperitoneal indgift og på 2 Sprague-Dau/ley-rotter, vægt 120-150 g, ved peroral indgift.
Bestemmelsen af LD 50 skete på grupper på hver 10 10 NMRI-mus, vægt 20 til 26 g, efter intraperitoneal ind gift. Iagttagelsesperioden var 14 dage.
Den omhandlede forbindelse er særdeles virksom som antiallergikum. Af tabel 1 fremgår, at forbindelsen efter peroral indgift er 227 gange mere virksomme end 15 sammenligningsforbindelsen (N-(4-phenyl-2-thiazolyl)~ oxamidsyre-2-ethylester, eksempel 1 i den europæiske patentoffentliggørelse 000 6368). Handelsforbindelsen Cromolyne er i disse forsøg uvirksom indtil 100 mg/kg peroralt.
20 Tabel 1
Antiallergisk virkning p.g akut toxicitet
Eks. Hæmning af PCA.. rotte, per os _LD 50 mq/kq_ nr. ED 50 mg/kg R.W. l) Mus i.p. Rotter p.o I 0,0382 227 956 >2 150 νχ 8,67 1 ca. 681 '-2 150
Cromo lyne 100 - >2 150 _____ I -- /
Relativ aktivitet.
På grund af den forbedrede aktivitet viser der sig en væsentlig større afstand mellem de toxiske og de virk- 149890 5 somme doser.
Til terapeutiske formål anvendes enkeltdoser på fra 0,1 til 100 mg.
Følgende eksempel belyser fremgangsmåden ifølge opfin-5 delsen nærmere.
EKSEMPEL
N-(4-phenyl-2-thiazolyl)-oxamidsyre-2-ethoxyethylester a) Til en opløsning af 17,6 g 2-amino-4-phenylthiazol i 100 ml methylenchlorid, 16,1 ml pyridin, 20 ml dimethyl-10 formamid dryppes ved 0 - 10 °C i løbet af 2 timer 19,8 g oxalsyre-2-ethoxyethylesterchlorid. Man omrører yderligere 1 time ved 10 °C og yderligere 1 time ved stuetemperatur og frasuger bundfaldet. Filtratet inddampes under formindsket tryk, og remanensen digereres med 15 fortyndet saltsyre. Der frasuges, vaskes med vand og tørres. Efter udkrystallisation med ethanol fås 13,4 g af forbindelsen med formlen I med smeltepunktet 110 °C.
b) 6,2 g N-(4-phenyl-2-thiazolyl)-oxamidsyre (fremstillet ud fra ethylesteren ved forsæbning med vandig kalium- 20 acetat og frigørelse af syren med fortyndet saltsyre) opvarmes i 25 ml tør toluen med 20 ml oxalylchlorid til 60 °C i 2 timer. Efter afdestillation af det overskydende oxalylchlorid under formindsket tryk tildrypper man en opløsning af 5,6 g ethylenglycolmonoethyléther, 25 3,5 ml triethylamin og 20 ml toluen. Man omrører 3 timer ved stuetemperatur og lader henstå natten over.
Bundfaldet frasuges, vaskes med methanol og vand og omkrystalliserés med ethanol. Der fås 3,3 g af forbindelsen med formel I med smeltepunktet 109-110 °C.
149890 6
Analyse for (320)
Beregnet: C 56,24 - H 5,03 - 0 19,98 - N 8,74 - S 10,01 Fundet: C 56,3 - H 5,0 - 0 19,6 - N 8,9 - S 10,1.
c) En suspension af 7,4 g N-(4-phenyl-2-aminothiazolyl)-5 oxamidsyre, 9,4 g ethylenglycolmonoethylether, 0,6 g p-toluensulfonsyre og 70 ml toluen opvarmes 6 timer med tilbagesvaling under vandudskillelse. Herefter afkøler man kolbeindholdet til 0 °C, frasuger bundfaldet og inddamper filtratet under formindsket tryk. Remanen-10 sen omrøres med 10 ml eddikeester, der frasuges, vaskes med cyclohexan og tørres. Der opnås 2,0 g af forbindelsen med formlen I med smeltepunkt 106 - 107 °C.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19803027527 DE3027527A1 (de) | 1980-07-19 | 1980-07-19 | Neue oxamidsaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel |
| DE3027527 | 1980-07-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK320081A DK320081A (da) | 1982-01-20 |
| DK149890B true DK149890B (da) | 1986-10-20 |
| DK149890C DK149890C (da) | 1987-04-21 |
Family
ID=6107684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK320081A DK149890C (da) | 1980-07-19 | 1981-07-17 | Analogifremgangsmaade til fremstilling af n-(4-phenyl-2-thiazolyl)-oxamidsyre-2-ethoxyethylester |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4407810A (da) |
| EP (1) | EP0044442B1 (da) |
| JP (1) | JPS5753475A (da) |
| AT (1) | ATE6256T1 (da) |
| CA (1) | CA1180705A (da) |
| DE (2) | DE3027527A1 (da) |
| DK (1) | DK149890C (da) |
| GR (1) | GR75239B (da) |
| IE (1) | IE51414B1 (da) |
| ZA (1) | ZA814902B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4511574A (en) * | 1981-01-08 | 1985-04-16 | Mitsui Toatsu Kagaku Kabushiki Kaisha | N-(4-Phenyl-2-thiazolyl)carbamate derivatives |
| IT1183061B (it) * | 1984-07-31 | 1987-10-05 | Zambon Spa | Composti dotati di attivita'antiallergica |
| IT1204959B (it) * | 1987-03-25 | 1989-03-10 | Zambon Farmaceutici Spa | Composti dotati di attivita' antiallergica |
| IT1204960B (it) * | 1987-03-25 | 1989-03-10 | Zambon Farmaceutici Spa | Composti dotati di attivita' antiallergica |
| ES2395682T3 (es) * | 2007-08-20 | 2013-02-14 | Symrise Ag | Derivados de ácido oxálico y su uso como principios activos refrescantes fisiológicos |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH460017A (de) * | 1965-03-05 | 1968-07-31 | Ciba Geigy | Verfahren zur Herstellung neuer Nitrothiazolverbindungen |
| DE2132431A1 (de) * | 1971-06-30 | 1973-01-11 | Riedel De Haen Ag | 4-phenyl-thiazolderivate enthaltende pharmazeutische praeparate |
| AR207563A1 (es) | 1973-03-23 | 1976-10-15 | American Home Prod | Procedimiento para preparar un nuevo ester de acido oxamico |
| US3966965A (en) * | 1973-03-23 | 1976-06-29 | American Home Products Corporation | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions |
| DE2601683C3 (de) * | 1976-01-17 | 1982-05-13 | Ytong AG, 8000 München | Kalk-Kieselsäure-Gemisch sowie Verfahren zur Herstellung von dampfgehärteten Baustoffen daraus |
| DE2656468A1 (de) | 1976-12-14 | 1978-06-15 | Boehringer Mannheim Gmbh | N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung |
| US4150140A (en) | 1976-12-23 | 1979-04-17 | The Upjohn Company | Benzothiazolyl oxanic acids, esters and salts |
| FR2429210A1 (fr) * | 1978-06-19 | 1980-01-18 | Fabre Sa Pierre | Derives de phenyl-4 thiazolyl-2 oxamates utiles dans le traitement de l'asthme |
| DE2828091A1 (de) * | 1978-06-27 | 1980-01-10 | Boehringer Sohn Ingelheim | 4-substituierte thiazoloxamsaeuren sowie ihre salze und ester |
-
1980
- 1980-07-19 DE DE19803027527 patent/DE3027527A1/de not_active Withdrawn
-
1981
- 1981-06-18 GR GR65267A patent/GR75239B/el unknown
- 1981-06-29 AT AT81105025T patent/ATE6256T1/de not_active IP Right Cessation
- 1981-06-29 EP EP81105025A patent/EP0044442B1/de not_active Expired
- 1981-06-29 DE DE8181105025T patent/DE3162277D1/de not_active Expired
- 1981-07-13 US US06/282,661 patent/US4407810A/en not_active Expired - Fee Related
- 1981-07-14 CA CA000381695A patent/CA1180705A/en not_active Expired
- 1981-07-16 IE IE1612/81A patent/IE51414B1/en unknown
- 1981-07-17 DK DK320081A patent/DK149890C/da active
- 1981-07-17 ZA ZA814902A patent/ZA814902B/xx unknown
- 1981-07-17 JP JP56110932A patent/JPS5753475A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0044442A1 (de) | 1982-01-27 |
| ZA814902B (en) | 1982-08-25 |
| CA1180705A (en) | 1985-01-08 |
| DK320081A (da) | 1982-01-20 |
| GR75239B (da) | 1984-07-13 |
| IE51414B1 (en) | 1986-12-24 |
| JPS5753475A (en) | 1982-03-30 |
| DE3162277D1 (en) | 1984-03-22 |
| EP0044442B1 (de) | 1984-02-15 |
| US4407810A (en) | 1983-10-04 |
| DE3027527A1 (de) | 1982-02-18 |
| ATE6256T1 (de) | 1984-03-15 |
| IE811612L (en) | 1982-01-19 |
| DK149890C (da) | 1987-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1299176C (en) | Process for preparing isoxazole and furan derivatives | |
| US3282938A (en) | 3-tertiary aminoloweralkyl-4-lower alkyl or phenyl-7-lower carbalkoxy lower alkyl or carboxy lower alkyl coumarins | |
| CN102030700B (zh) | 苯甲酰胺基羧酸类化合物及其制法和药物用途 | |
| US6437143B2 (en) | Thiazolidone-2 derivatives, 4-diketone substituted, method for obtaining them and pharmaceutical compositions containing same | |
| JPS6251272B2 (da) | ||
| EP1142885A1 (en) | Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives | |
| PT1502590E (pt) | Derivados de oximas heterocíclicas, processo para a sua preparação, e sua utilização no tratamento do diabetes de tipo ii | |
| FI83650C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 4-(isoxazolyl)-tiazol-2-oxaminsyraderivat. | |
| CA1173838A (en) | Tricyclic thiazolyloxamic acids and their derivatives, their preparation, and therapeutic agents containing these compounds | |
| DE69523595T2 (de) | Aryl und heteroaryl alkoxynaphtalen derivate | |
| AU752993B2 (en) | Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them | |
| ES2318727T3 (es) | Nuevos derivados de oximas heterociclicas, su procedimiento de preparacion y su utilizacion como agentes hipoglucemicos e hipolipidemicos. | |
| JPS6231706B2 (da) | ||
| EMERSON et al. | Some 2-Acetylthiophene Derivatives And Related Acetophenone Analogs | |
| WO2014092514A1 (ko) | 신규한 화합물, 이의 약학적으로 허용가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 | |
| SU1470186A3 (ru) | Способ получени гетероциклических соединений | |
| Ammar et al. | Cyanoacetanilide intermediate in heterocyclic synthesis, part 8: preparation of thiazolidine, benzo [d][1, 3] oxazine, 4-aminothiophene and 4-aminothiazole derivatives strating from 2-(2-cyanoacetamido)-benzoate | |
| JPH04297466A (ja) | テトラゾール誘導体及び医薬 | |
| EP0397169B1 (en) | Novel benzothiazole derivatives | |
| JPH0440348B2 (da) | ||
| US3300507A (en) | Benzotfflazolylbenzene amides | |
| US3243442A (en) | 7-hydroxy coumarin deriv atives | |
| KR810001978B1 (ko) | 2, 5-디히드로-1, 2티아지노 [5, 6-b]인돌-3-카복사미드-1, 1-디옥사이드의제조 방법 | |
| KR850001352B1 (ko) | 벤즈옥사졸의 제조방법 | |
| JPH01193253A (ja) | 置換イミダゾール化合物 |